Organon Enters Into Distribution Agreement For Anzemet(R)
Published: Dec 05, 2005
ROSELAND, N.J., Dec. 5 /PRNewswire/ -- Today Organon USA Inc., a business unit of Akzo Nobel NV, announced that they have entered into a distribution agreement for Anzemet(R) Injection (dolasetron mesylate injection) with Aventis Pharmaceuticals Inc., a member of the sanofi-aventis Group, which will be become effective January 1, 2006.
Organon USA Inc. will be responsible for the marketing, sales, and managed markets activities including pricing and contracting as well as recording sales for Anzemet(R) Injection for use in the prevention and treatment of postoperative nausea and/or vomiting (PONV). Organon USA will promote Anzemet Injection to the anesthesia community within the hospital market for PONV.
"Organon is very excited about our agreement with sanofi-aventis for Anzemet(R) for PONV. We have a well-established commitment in anesthesia and we have maintained a leadership position with Zemuron(R) (rocuronium bromide) for injection. Anzemet Injection will be a valued addition to our anesthesia portfolio," said Michael Novinski, president of Organon USA Inc.
ANZEMET Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high dose cisplatin; the prevention of postoperative nausea and vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ANZEMET Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low; and the treatment of postoperative nausea and/or vomiting.
The most common adverse events (greater than or equal to) in postoperative patients are headache, dizziness, and hypotension. Anzemet(R) can cause ECG interval changes; it should be administered with caution in patients who have or may develop prolongation of cardiac conduction intervals.
Organon, with shared head offices in Roseland, NJ, USA and Oss, The Netherlands creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel. For more information about Organon, please go to http://www.organon-usa.com.
This report contains statements which address such key issues as Organon's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the "Outlook," should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.
For a more complete discussion of the risk factors affecting our business please see the Akzo Nobel Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company's website http://www.akzonobel.com.
* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.Organon USA Inc.
CONTACT: Frances DeSena of Organon Pharmaceuticals USA Inc.,+1-973-325-4500, firstname.lastname@example.org